Therapeutic and diagnostic agent delivery

• US 5,997,525 A
• Filed: 06/29/1998
• Issued: 12/07/1999
• Est. Priority Date: 06/07/1995
• Status: Expired due to Term

• Current Assignee: Cryolife Incorporated
• Original Assignee: Cardiogenesis Corporation (Cryolife Incorporated)
• Inventors: Smith, Craig, Kesten, Randy, March, Keith L., Aita, Michael
• Primary Examiner(s): Coggins, Wynn Wood
• Assistant Examiner(s): Blyveis, Deborah
• Application Number:
  US09/107,079
• Time in Patent Office: 526 Days
• Field of Search: 604/96-103, 604/49, 604/28, 604/51-53, 604/22, 606/7, 606/15, 606/192, 606/194, 607/89, 607/119, 607/120, 607/122
• US Class Current: 604/508
• CPC Class Codes: A61B 18/24 with a catheter A61B18/26, A61B18/28 take precedence
• CPC Class Codes: A61B 2017/00247 Making holes in the wall of the heart, e.g. laser Myocardial revascularization
• CPC Class Codes: A61B 2017/22082 after introduction of a substance
• CPC Class Codes: A61B 2018/00392 Transmyocardial revascularisation
• CPC Class Codes: A61M 2210/125 Heart
• CPC Class Codes: A61M 37/00 Other apparatus for introducing media into the body for reproduction or fertilisation A61B17/425; apparatus for iontophoresis or cataphoresis A61N1/30; Percutany, i.e. introducing medicines into the body by diffusion through the skin salt baths A61H33/04

Abstract

A system for treating a patient'"'"'s heart which comprises a means to form channels in the heart wall and a means to deliver a therapeutic or diagnostic agent into the channels. Additionally, the system may comprise a means to retain the agent within the channels for a useful period of time. The system may be configured to be introduced percutaneously or intraoperatively. The system generally comprises an elongated, flexible lasing transmission means having a laser radiation emitting means and an delivery lumen opening at the distal end. Practice of the invention comprises forming channels in the heart wall and delivering a therapeutic or diagnostic agent into the channel. Gene therapy agents of this invention comprise vectors for transferring genetic information to the heart tissue in vivo or harvested cells which have been genetically engineered in vitro. Additionally, the invention may comprise retaining the agent within the channels, for example, by incorporating the agent in a viscous carrier.

Claims

1. A method for treating a patient'"'"'s heart comprising:

a) forming a channel within a region of a wall of the patient'"'"'s heart which includes a myocardial layer; and

b) contacting heart tissue within the region of the heart adjacent the formed channel with an angiogenic agent.

2. The method of claim 1 comprising contacting the heart tissue within said region with a angiogenic agent selected from the group consisting of vascular endothelial growth factor, acidic and basic fibroblast growth factor, and angiogenin.

3. A method for treating a patient'"'"'s heart comprising:

a) ablating tissue in a wall of the patient'"'"'s heart; and

b) delivering an angiogenic agent into the heart wall.

4. The method of claim 3 wherein the angiogenic agent is selected from the group consisting of vascular endothelial growth factor, acidic and basic fibroblast growth factor, and angiogenin.

5. The method of claim 3 wherein a channel is formed within the heart wall when the tissue of the heart wall is ablated.

6. The method of claim 5 wherein the angiogenic agent is delivered into the heart wall through the channel formed therein.

7. The method of claim 6 wherein the angiogenic agent is delivered into the channel formed in the heart wall through a catheter having a distal end, a discharge port in the distal end and a lumen extending therein to the port in the distal end.

8. The method of claim 7 wherein the distal end of the catheter is advanced into the channel formed in the patient'"'"'s heart wall to deliver angiogenic agent therein.